European Companies Search Engine

UK funding (£391,650): Translation of Step-changing Bioprocesses and Expression System Technologies for Next Generation Protein Biologics Production in CHO Cells Ukri1 Sept 2016 UK Research and Innovation, United Kingdom

Overview

Text

Translation of Step-changing Bioprocesses and Expression System Technologies for Next Generation Protein Biologics Production in CHO Cells

Abstract Chinese hamster ovary (CHO) cells are the main production host for >US$145billion/yr of protein biologics used as medicines for a range of diseases. The CHO platform is mature when considering production of monoclonal antibodies, but new format non-native molecules such as fusion proteins, antibody fragments and other exotic molecules remain difficult to express (DTE) in this, or any other host. This project builds upon proof of concept work demonstrating that engineering the CHO chassis, together with growth media manipulation, increases both the yield and quality of a number of DTE proteins that are in development for application to unmet clinical needs and diseases with no current treatments. The project will advance the technology readiness level of our preliminary findings beyond proof-of-concept to deliver the commercialization of new CHO cell systems for DTE proteins and associated bioprocesses ready for industrial application to produce these important new medicines.
Category Collaborative R&D
Reference 102621
Status Closed
Funded period start 01/09/2016
Funded period end 29/02/2020
Funded value £391,650.00
Source https://gtr.ukri.org/projects?ref=102621

Participating Organisations

LONZA BIOLOGICS PLC

£391,650.00

UNIVERSITY OF KENT

The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Lonza Biologics plc, Slough.